AngIV-6a

AngIV-6a is a synthetic, macrocyclic peptide analog of Angiotensin IV (Ang IV) that acts as a potent and selective inhibitor of Insulin-regulated aminopeptidase (IRAP), also known as the AT4 receptor. Developed by researchers at Monash University, AngIV-6a was engineered to improve the metabolic stability and bioavailability of the native Ang IV peptide, which is rapidly degraded in vivo. By inhibiting the enzymatic activity of IRAP, AngIV-6a facilitates the accumulation of various neuropeptides, such as vasopressin and oxytocin, which are involved in memory processing and cognitive function. Preclinical studies have demonstrated that AngIV-6a can enhance spatial memory and reverse cognitive deficits in animal models of Alzheimer's disease and scopolamine-induced amnesia, making it a significant lead compound for the development of cognitive enhancers.

Other names

macrocyclic Ang IV analog